Biogen Announces Positive Two-Year Phase 2 Data for Diranersen in Early Alzheimer's Disease

11/17/2026
Impact: 65
Healthcare

Biogen reported positive two-year Phase 2 CELIA study results for investigational tau-targeting therapy diranersen in early Alzheimer’s disease. At Week 96, the 60 mg twice-yearly regimen slowed decline on the CDR-SB scale by 38% versus placebo, a 1.09-point treatment difference, with reported benefits across cognition, function and disease progression. Biogen is evaluating diranersen as a potential approach targeting core Alzheimer’s pathologies.

AI summary, not financial advice

Share: